Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 181

Sort by

Sort Order Select

Journal Articles

A phase 2 study of interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract

Blood (2023) 141 (12): 1389–1401.

https://doi.org/10.1182/blood.2021015111

Published: 2023

Includes: Supplemental data

Journal Articles

Progressive multifocal leukoencephalopathy in patients treated with chimeric antigen receptor T cells

Adam Goldman, Emanuel Raschi, Joab Chapman, Bianca D. Santomasso, Marcelo C. Pasquini, Miguel-Angel Perales, Roni Shouval

Blood (2023) 141 (6): 673–677.

https://doi.org/10.1182/blood.2022017386

Published: 2023

Includes: Supplemental data

Journal Articles

Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703

Blood (2022) 140 (Supplement 2): LBA-4.

https://doi.org/10.1182/blood-2022-171463

Published: 2022

Journal Articles

Preservation of the fecal microbiome is associated with reduced severity of graft-versus-host disease

Blood (2022) 140 (22): 2385–2397.

https://doi.org/10.1182/blood.2021015352

Published: 2022

Includes: Supplemental data

Journal Articles

Multicenter Phase I Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia

Leland Metheny, Ronald M. Sobecks, Christina Cho, Jiasheng Wang, Lisa Ciarrone, Paolo F. Caimi, Folashade Otegbeye, Brenda W. Cooper, Molly Gallogly, Ehsan Malek, Aaron T. Gerds, Betty K. Hamilton, Sergio A Giralt, Miguel-Angel Perales, Marcos J.G. de Lima

Blood (2022) 140 (Supplement 1): 1887–1889.

https://doi.org/10.1182/blood-2022-169935

Published: 2022

Journal Articles

Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell Therapy (CART)

Blood (2022) 140 (Supplement 1): 4636–4638.

https://doi.org/10.1182/blood-2022-169452

Published: 2022

Journal Articles

Outcomes and Management of Sars-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation (HCT) and CAR-T Therapy

Maria Stefania Infante, Susan DeWolf, Roni Tamari, Parastoo B. Dahi, Yeon Joo Lee, Ioannis Politikos, Juliet N. Barker, N. Esther Babady, Lakshmi Ramanathan, Susan Seo, Sergio A. Giralt, Mini Kamboj, Miguel-Angel Perales, Gunjan L. Shah

Blood (2022) 140 (Supplement 1): 4792–4794.

https://doi.org/10.1182/blood-2022-166393

Published: 2022

Journal Articles

Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Leukemia

Shlomo Elias, Moneeza Walji, Samantha Brown, Sean M. Devlin, Esperanza B. Papadopoulos, Ann A Jakubowski, Doris M Ponce, James W. Young, Sergio A Giralt, Miguel-Angel Perales, Brian C. Shaffer, Parastoo B. Dahi, Richard J. Lin, Christina Cho, Roni Tamari, Melody Smith, Boglarka Gyurkocza

Blood (2022) 140 (Supplement 1): 10627–10628.

https://doi.org/10.1182/blood-2022-170088

Published: 2022

Journal Articles

Estimating the Lifetime Medical Cost Burden of an Allogeneic Hematopoietic Cell Transplantation Patient and the Value of Addressing the Unmet Need

Richard T. Maziarz, Steven M Devine, Louis P. Garrison, Irene Agodoa, Jack Badaracco, Matthew Gitlin, Miguel-Angel Perales

Blood (2022) 140 (Supplement 1): 10833–10834.

https://doi.org/10.1182/blood-2022-157439

Published: 2022

Journal Articles

Tracking Immune Reconstitution in the Bone Marrow Following Allogeneic Hematopoietic Transplantation in Humans Reveals Early Dominance of Innate Lymphoid Populations

Blood (2022) 140 (Supplement 1): 4759–4761.

https://doi.org/10.1182/blood-2022-159303

Published: 2022

Journal Articles

Cytokine Release Syndrome (CRS) Is Not Required for CAR-T Cell Efficacy in Aggressive Large B-NHL

Shakthi Bhaskar, Vivek Patel, David L. Porter, Stephen J. Schuster, Loretta J. Nastoupil, Miguel-Angel Perales, Ana Alarcon Tomas, Michael R. Bishop, Joseph P. McGuirk, Richard T. Maziarz, Andy Chen, Veronika Bachanova, Peter A. Riedell, Olalekan O. Oluwole

Blood (2022) 140 (Supplement 1): 10971–10973.

https://doi.org/10.1182/blood-2022-155886

Published: 2022

Journal Articles

Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies

Blood (2022) 140 (Supplement 1): 10357–10359.

https://doi.org/10.1182/blood-2022-162539

Published: 2022

Journal Articles

Predictors and Implications of Renal Injury in Large Cell Lymphoma Patients Receiving CD19 CAR T Cell Therapy

Blood (2022) 140 (Supplement 1): 4671–4672.

https://doi.org/10.1182/blood-2022-157455

Published: 2022

Journal Articles

Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative

Blood (2022) 140 (Supplement 1): 9057–9060.

https://doi.org/10.1182/blood-2022-169307

Published: 2022

Journal Articles

Correlative Biomarkers for CART19 Response in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 9228–9230.

https://doi.org/10.1182/blood-2022-163333

Published: 2022

Journal Articles

Outcomes of Subsequent Anti-Lymphoma Therapies in Patients (Pts) with Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel) or Standard of Care (SOC) in the Second-Line (2L) ZUMA-7 Study

Armin Ghobadi, Javier Munoz, Jason Westin, Frederick L. Locke, David B. Miklos, Aaron P. Rapoport, Miguel-Angel Perales, Patrick M. Reagan, Joseph P. McGuirk, Caron A. Jacobson, Marie José Kersten, Irit Avivi, Andrew Peng, Marco Schupp, Christina To, Olalekan O. Oluwole

Blood (2022) 140 (Supplement 1): 1595–1597.

https://doi.org/10.1182/blood-2022-158303

Published: 2022

Journal Articles

Population Pharmacokinetic Model Identifies an Optimal Fludarabine Exposure for Improved Outcomes after CD19-Directed CAR T Cell Therapy for Aggressive B-NHL: Analysis from the Cell Therapy Consortium

Blood (2022) 140 (Supplement 1): 1588–1591.

https://doi.org/10.1182/blood-2022-164674

Published: 2022

Journal Articles

Predictors and Outcomes of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Aggressive B-Cell Non-Hodgkin Lymphoma

Vivek Patel, Shakthi Bhaskar, Stephen J. Schuster, Loretta J. Nastoupil, Miguel-Angel Perales, Roni Shouval, Joseph P. McGuirk, Richard T. Maziarz, Andy Chen, Veronika Bachanova, David L. Porter, Michael R. Bishop, Peter A. Riedell, Olalekan O. Oluwole

Blood (2022) 140 (Supplement 1): 366–368.

https://doi.org/10.1182/blood-2022-165556

Published: 2022

Journal Articles

A Phase 2/3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study of NKTR-255 Vs Placebo Following CD-19 Directed CAR-T Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Miguel-Angel Perales, Sairah Ahmed, Saurabh Dahiya, Peter A. Riedell, Joseph P. McGuirk, Olalekan O. Oluwole, Sohail A. Chaudhry, Zachary Lee, Stanley Dai, Neha Dixit, Christie Fanton, Mario Q. Marcondes, Jonathan Zalevsky, Mary A. Tagliaferri, Cameron J. Turtle

Blood (2022) 140 (Supplement 1): 7488–7490.

https://doi.org/10.1182/blood-2022-162511

Published: 2022

Journal Articles

Severe Persistent Cytopenias Following CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma

Magdalena Corona De Lapuerta, Roni Shouval, Ana Alarcon Tomas, Jessica R. Flynn, Sean M. Devlin, Connie Lee Batlevi, Joshua A Fein, Sergio A Giralt, Richard J. Lin, Karthik Nath, Maria Lia Palomba, Allison Parascondola, Gunjan L. Shah, Gilles Salles, Michael Scordo, Moneeza Walji, Miguel-Angel Perales, Parastoo B Dahi

Blood (2022) 140 (Supplement 1): 12770–12772.

https://doi.org/10.1182/blood-2022-163457

Published: 2022

NARROW

A phase 2 study of interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract

Progressive multifocal leukoencephalopathy in patients treated with chimeric antigen receptor T cells

Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703

Preservation of the fecal microbiome is associated with reduced severity of graft-versus-host disease

Multicenter Phase I Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia

Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell Therapy (CART)

Outcomes and Management of Sars-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation (HCT) and CAR-T Therapy

Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Leukemia

Estimating the Lifetime Medical Cost Burden of an Allogeneic Hematopoietic Cell Transplantation Patient and the Value of Addressing the Unmet Need

Tracking Immune Reconstitution in the Bone Marrow Following Allogeneic Hematopoietic Transplantation in Humans Reveals Early Dominance of Innate Lymphoid Populations

Cytokine Release Syndrome (CRS) Is Not Required for CAR-T Cell Efficacy in Aggressive Large B-NHL

Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies

Predictors and Implications of Renal Injury in Large Cell Lymphoma Patients Receiving CD19 CAR T Cell Therapy

Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative

Correlative Biomarkers for CART19 Response in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Outcomes of Subsequent Anti-Lymphoma Therapies in Patients (Pts) with Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel) or Standard of Care (SOC) in the Second-Line (2L) ZUMA-7 Study

Population Pharmacokinetic Model Identifies an Optimal Fludarabine Exposure for Improved Outcomes after CD19-Directed CAR T Cell Therapy for Aggressive B-NHL: Analysis from the Cell Therapy Consortium

Predictors and Outcomes of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Aggressive B-Cell Non-Hodgkin Lymphoma

A Phase 2/3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study of NKTR-255 Vs Placebo Following CD-19 Directed CAR-T Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Severe Persistent Cytopenias Following CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only